Eyeworld

SEEK AN ALTERNATIVE OPTION Indications And Usage iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). ©2025 Glaukos Corporation. All rights reserved. Glaukos and iDose are registered trademarks of Glaukos Corporation. PM-US-2920 References: 1. Sarkisian SR et al. Ophthalmol Ther. 2024;13(4):995-1014. 2. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. 3. Bacharach J et al. Glaucoma Today. 2020:40-43. 4. Berdahl JP et al. Drugs. 2024;84(1):83-97. IMPORTANT SAFETY INFORMATION Dosage And Administration For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions. Contraindications iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product. Warnings And Precautions iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent. Adverse Reactions In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity. Please see full Prescribing Information. You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644. View full Prescribing Information at iDoseTRhcp.com Drowning from the burdens of drops? • Designed to deliver up to 3 years of continuous IOP control 4 • Helps reduce many of the burdens of drops—compliance issues, possible disease progression, and administrative headaches 4 • Introduces your patients to interventional glaucoma without the need for drops 1 iDose TR is a game-changing procedural pharmaceutical that enables earlier intervention 2,3 Actual size of implant: 1.8 mm x 0.5 mm Rise above the flood. With iDose TR, 8 of 10 patients were completely free of prescription eye drops at 12 months. 1

• Blank Page
• Blank Page (1)